Focus: Vantive is a biotechnology company specializing in vital organ therapy products and digital solutions, with a focused presence in nephrology based in Deerfield, IL. The company maintains a portfolio of established dialysis solutions (DIANEAL, PRISMASOL) and emerging therapeutic technologies.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Vantive to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Core peritoneal dialysis solution with approaching loss of exclusivity, representing legacy revenue base at risk.
Help build intelligence for Vantive
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vantive's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Variant formulation of flagship peritoneal dialysis product facing generic competition imminently.
High-dextrose concentration variant of DIANEAL portfolio, approaching loss of market exclusivity.
Multi-formulation acute care dialysate portfolio with multiple variants approaching generic entry.
17 discontinued, 19 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo